| Listing of Equity Shares of Gland Pharma Limited |
Trading Members of the Exchange are hereby informed that effective from Friday, November 20, 2020, the equity shares of Gland Pharma Limited shall be listed and admitted to dealings on the Exchange in the list of 'B' Group of Securities.
|
Name of the company
|
Gland Pharma Limited
|
|
Registered Office
|
Sy. No. 143 - 148, 150 and 151,
Near Gandi Maisamma ‘X’ Roads, D.P.Pally, Dundigal, Dundigal-Gandi Maisamma (M), Medchal-Malkajgiri District,
Hyderabad - 500 043, Telangana, India
Tel: +91 40 3051 0999
Email: investors@glandpharma.com
Website: www.glandpharma.com
|
|
No. of Securities
|
163,282,823 Equity Shares of Rs.1/- each fully paid up
|
|
Distinctive Number range
|
1 to 163282823
|
|
Scrip ID on BOLT System
|
GLAND
|
|
Abbreviated Name on BOLT System
|
GLAND
|
|
Scrip Code
|
543245
|
|
ISIN
|
INE068V01023
|
|
Market Lot
|
1
|
|
Issue Price for the current Public issue
|
Rs. 1500/- per share (Face Value of Rs. 1/- and premium of Rs. 1,499/-)
|
|
Date of Allotment in the public issue
|
November 17, 2020
|
|
Pari Pasu
|
Yes
|
|
Financial Year
|
Mar-31
|
|
Lock in detail
|
As per Annexure I
|
|
Shareholding Pattern
|
As per Annexure II
|
a) Trading Members may note that as per the guidelines issued by SEBI dated February 16, 2000, securities of the company will only be traded in Dematerialised form.
b) Further the trading members may please note that the above-mentioned scrip will be a part of Special Pre-open Session (SPOS) on Friday, November 20, 2020. For further information on SPOS, the trading members are requested to refer to the Exchanges notice no. 20120216-29 dated February 16, 2012 on Enabling Special Pre-open Session for IPOs & Relisted Scrips
c) The company has informed the Exchange that in respect of shares in physical form, the respective share certificates have been enfaced with their non-transferability. The company has informed the Exchange that in respect of shares in demat form, necessary corporate action has been executed to have the lock-in period marked in the depository’s records.
d) The Registrar to the issue as mentioned in the prospectus is given below:
e) In case members require any clarifications on the subject matter of this notice, they may please contact any of the following:
|
a) At the company:
Sampath Kumar Pallerlamudi,
Company Secretary and Compliance Officer
|
Address:
Sy. No. 143 - 148, 150 and 151,
Near Gandi Maisamma ‘X’ Roads, D.P.Pally, Dundigal, Dundigal-Gandi Maisamma (M), Medchal-Malkajgiri District,
Hyderabad - 500 043, Telangana, India
Tel: +91 40 3051 0999
Email: investors@glandpharma.com
Website: www.glandpharma.com
|
|
b) At the Exchange:
Ms. Rupal Khandelwal
Senior Manager
|
Tel.: (91) 022 2272 8262
|
Rupal Khandelwal
Senior Manager
Thursday, November 19, 2020
|